← Back to guidelines
Pathology3 papers

Argentinian hemorrhagic fever

Last edited:

Overview

Argentinian hemorrhagic fever (AHF) is a severe viral hemorrhagic fever caused by Junin virus, an arenavirus primarily endemic to rural areas of Argentina. The virus is transmitted to humans mainly through contact with excreta of infected rodents, particularly the Calomys musculinus, which serves as the natural reservoir. AHF can lead to significant morbidity and mortality, characterized by fever, hemorrhagic manifestations, and potential neurological complications. Understanding the pathophysiology, epidemiology, clinical presentation, and diagnostic approaches is crucial for effective management and prevention of this disease.

Pathophysiology

The pathophysiology of Argentinian hemorrhagic fever is intricately linked to the viral tropism and replication dynamics within host tissues, particularly the lymphatic system. Junin virus preferentially infects macrophages and dendritic cells in the spleen, as highlighted by studies demonstrating extensive viral replication in these cell types [PMID:6309667]. This tropism is critical because macrophages play a pivotal role in the innate immune response, and dendritic cells are essential for initiating adaptive immunity. The pathogenic strain's ability to infect both macrophages and dendritic cells likely contributes to its virulence by disrupting both innate and adaptive immune mechanisms, leading to a more severe clinical course.

In contrast, attenuated strains of Junin virus predominantly target dendritic cells, suggesting that the broader cellular tropism of the pathogenic strain may be a key factor in its enhanced pathogenicity [PMID:6309667]. This differential cell tropism implies that the extent and nature of immune system impairment could vary significantly between different strains, influencing the severity and progression of the disease. Furthermore, Candurra et al. [PMID:2177565] observed distinct differences in cytopathogenicity between virulent and attenuated strains, indicating that strain-specific properties may dictate the extent of tissue damage and clinical manifestations observed in patients. Chronic systemic infection, evidenced by persistent viral presence in multiple organs up to 480 days post-infection in surviving Calomys musculinus [PMID:2825553], underscores the potential for long-term sequelae and underscores the importance of prolonged monitoring in human cases.

Epidemiology

Argentinian hemorrhagic fever predominantly affects rural populations in Argentina, with significant ecological and environmental factors influencing its spread. The natural reservoir, Calomys musculinus, plays a crucial role in maintaining the virus within endemic regions. Epidemiological studies reveal a high mortality rate among infected rodents, with approximately 70% mortality observed between days 24-40 post-infection [PMID:2825553]. This high mortality rate in the reservoir host suggests a robust viral replication cycle and underscores the potential for frequent viral shedding, increasing the risk of human exposure.

Human infection often occurs through occupational exposure, such as agricultural work or rodent control activities, where contact with infected rodent excreta is common. The impact on rodent populations extends beyond mortality, with a marked reduction in reproductive efficiency noted among infected Calomys musculinus, where only 13.3% of mating pairs produced offspring compared to 60% in uninfected controls [PMID:2825553]. This reproductive impairment not only affects the rodent population dynamics but also indirectly influences the transmission dynamics of Junin virus, potentially leading to periods of increased human risk due to altered rodent behavior and distribution patterns.

Clinical Presentation

The clinical presentation of Argentinian hemorrhagic fever can vary widely, ranging from mild flu-like symptoms to severe hemorrhagic and neurological complications. Early symptoms typically include fever, headache, myalgia, and malaise, which can mimic other febrile illnesses, complicating early diagnosis. Notably, while studies in animal models did not explicitly document overt neurological signs [PMID:2825553], there is a suggestion of subtle neurological involvement given the observed weight loss during lactation and increased mortality in infected animals, hinting at potential covert neurological impacts that may manifest differently in humans.

Hemorrhagic manifestations, a hallmark of AHF, can include petechiae, ecchymoses, and gastrointestinal bleeding, reflecting the virus's ability to disrupt vascular integrity. The systemic nature of the infection, evidenced by viral presence in multiple organs over extended periods [PMID:2825553], suggests that patients may experience multisystem involvement, including renal and hepatic dysfunction, further complicating clinical management. The subtle clinical presentations observed in animal models imply that clinicians should maintain a high index of suspicion, especially in endemic areas, to promptly identify and manage AHF before severe complications arise.

Diagnosis

Diagnosing Argentinian hemorrhagic fever requires a multifaceted approach, leveraging both clinical suspicion and laboratory confirmation. Given the differential tropism of Junin virus strains—pathogenic strains infecting both macrophages and dendritic cells, while attenuated strains primarily target dendritic cells [PMID:6309667]—diagnostic strategies should focus on detecting viral antigens or nucleic acids in these cell types. Serological tests, including enzyme-linked immunosorbent assays (ELISA) and immunofluorescence assays, remain foundational for detecting antibodies against Junin virus, particularly useful in later stages of infection when seroconversion occurs.

Molecular diagnostics, such as reverse transcription polymerase chain reaction (RT-PCR), offer high sensitivity and specificity for detecting viral RNA in blood or other bodily fluids, facilitating early diagnosis [PMID:2177565]. Candurra et al. [PMID:2177565] identified strain-specific differences in the surface glycoprotein GP38, which could be exploited for more precise strain differentiation in clinical settings. This molecular distinction is crucial for tailoring therapeutic approaches and understanding disease progression based on viral strain characteristics. Additionally, histopathological examination of affected tissues, particularly those rich in macrophages and dendritic cells, may reveal characteristic viral inclusions, supporting a definitive diagnosis when combined with clinical and laboratory findings.

Management

The management of Argentinian hemorrhagic fever primarily focuses on supportive care and specific antiviral interventions, given the limited availability of definitive treatments. Early recognition and prompt hospitalization are critical to mitigate severe complications. Supportive care includes fluid resuscitation to manage hypovolemic shock, blood transfusions for significant hemorrhage, and monitoring for organ dysfunction, particularly renal and hepatic failure. Close attention to electrolyte imbalances and acid-base status is essential due to the systemic nature of the disease.

Antiviral therapy, while not yet standardized, may involve ribavirin, which has shown some efficacy in treating other arenavirus infections [PMID:2177565]. However, the optimal dosing and duration require further clinical validation specific to Junin virus. Adjunctive therapies aimed at reducing viral load and mitigating immune dysregulation are under investigation but remain experimental. Given the potential for chronic viral persistence observed in animal models [PMID:2825553], long-term follow-up and monitoring for delayed complications are advisable in survivors.

Key Recommendations

  • Early Recognition and Rapid Diagnosis: Clinicians in endemic areas should maintain a high index of suspicion for AHF, especially during outbreaks or in patients with unexplained hemorrhagic symptoms. Utilize serological tests and molecular diagnostics to confirm the diagnosis promptly.
  • Supportive Care: Emphasize comprehensive supportive care, including fluid management, blood transfusions, and monitoring for organ dysfunction, to stabilize patients and manage acute complications effectively.
  • Antiviral Therapy: Consider ribavirin as part of the treatment regimen, guided by clinical response and monitoring for adverse effects, while awaiting further evidence-based guidelines specific to Juni virus infections.
  • Preventive Measures: Implement robust rodent control measures and educate communities about safe practices to minimize exposure to infected rodent excreta, reducing the risk of human infection.
  • Long-term Monitoring: Survivors should undergo regular follow-up to detect and manage potential long-term sequelae, given the evidence of chronic viral presence in multiple organs [PMID:2825553].
  • References

    1 Laguens M, Chambó JG, Laguens RP. In vivo replication of pathogenic and attenuated strains of Junin virus in different cell populations of lymphatic tissue. Infection and immunity 1983. link 2 Candurra NA, Scolaro LA, Mersich SE, Damonte EB, Coto CE. A comparison of Junin virus strains: growth characteristics, cytopathogenicity and viral polypeptides. Research in virology 1990. link90083-u) 3 Vitullo AD, Hodara VL, Merani MS. Effect of persistent infection with Junin virus on growth and reproduction of its natural reservoir, Calomys musculinus. The American journal of tropical medicine and hygiene 1987. link

    Original source

    1. [1]
    2. [2]
      A comparison of Junin virus strains: growth characteristics, cytopathogenicity and viral polypeptides.Candurra NA, Scolaro LA, Mersich SE, Damonte EB, Coto CE Research in virology (1990)
    3. [3]
      Effect of persistent infection with Junin virus on growth and reproduction of its natural reservoir, Calomys musculinus.Vitullo AD, Hodara VL, Merani MS The American journal of tropical medicine and hygiene (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG